JOURNEY II XR Safety and Effectiveness PMCF

Sponsor
Smith & Nephew, Inc. (Industry)
Overall Status
Active, not recruiting
CT.gov ID
NCT03136887
Collaborator
(none)
176
14
140.1
12.6
0.1

Study Details

Study Description

Brief Summary

This study was designed to demonstrate the safety and performance of the JOURNEY II XR total knee system by evaluating implant survival rates at 10 years using Kaplan-Meier analysis. All participants will be implanted with the JOURNEY II XR total knee system.

Detailed Description

Total knee arthroplasty (TKA) is considered the most beneficial and cost-effective treatment for end-stage knee arthritis and is the most frequently performed joint replacement surgery. TKA is also indicated for earlier osteoarthritis (OA) interventions, such as osteotomy or unicompartmental replacement, when additional treatment is warranted. One device option available once the decision is made to perform TKA is the JOURNEY II XR Total Knee System. The JOURNEY II XR Total Knee System is designed to be a more "natural feeling" total knee replacement. The goal of the JOURNEY II XR is to enable a higher level of function after total knee replacement by relieving pain and restoring the ability to participate in active lifestyles. The main aim of this study is to generate long-term safety and performance data for the JOURNEY™ II XR Total Knee System. Effectiveness information such as short- and long-term function, subject satisfaction, and quality of life will also be measured.

Study Design

Study Type:
Observational
Actual Enrollment :
176 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
A Prospective, Multicenter, Post-Market Clinical Follow-Up Study to Evaluate the Safety and Effectiveness of the JOURNEY™ II XR Total Knee System
Actual Study Start Date :
Jul 28, 2017
Anticipated Primary Completion Date :
Apr 1, 2029
Anticipated Study Completion Date :
Apr 1, 2029

Arms and Interventions

Arm Intervention/Treatment
JOURNEY II XR TKA

This is a single arm study, all subjects will receive JOURNEY II XR TKA

Device: JOURNEY II XR Total Knee System
JOURNEY II XR Total Knee System

Outcome Measures

Primary Outcome Measures

  1. Implant survival rate [10 years]

    Did knee survive with no revision through 10 years

Secondary Outcome Measures

  1. Knee function [10 years]

    Lateral Step-Up Test

  2. Quality of Life - EQ-5D - 3L [10 years]

    Patient Reported Outcomes using EuroQol Five Dimensions Questionnaire (EQ-5D - 3L) questionnaire

  3. Quality of Life - FJS [10 years]

    Patient Reported Outcomes using Forgotten Joint Score (FJS) questionnaire

  4. Quality of Life - KOOS [10 years]

    Patient Reported Outcomes using Knee Injury and Osteoarthritic Outcome Scores (KOOS) questionnaire

  5. Quality of Life - ABC scale [10 years]

    Patient Reported Outcomes using Activities-specific Balance Confidence (ABC) questionnaire

  6. Quality of Life - SAPSS [10 years]

    Patient Reported Outcomes using Self-Administered Patient Satisfaction Score (SAPSS) questionnaire

  7. Physiotherapy (PT) utilization - No. of visits [6 Months Post-operatively]

    Number of PT visits required up to 6 months after surgery

  8. Physiotherapy (PT) utilization - Period of visits [6 Months Post-operatively]

    Time period during which PT appointments are required up to 6 months after surgery

  9. Radiographic outcomes [10 years]

    X-rays of index joint

  10. Adverse Events (AEs) [10 years]

    All AEs will be collected and reported

Eligibility Criteria

Criteria

Ages Eligible for Study:
22 Years to 75 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  1. require TKA due to rheumatoid arthritis, post-traumatic arthritis, osteoarthritis, or degenerative arthritis, failed osteotomies, or failed unicompartmental replacement

  2. have all cruciate and collateral ligaments intact in the index joint

  3. adult patients that in the judgement of the Investigator are skeletally mature

  4. be willing and able to participate in required follow-up visits at the investigational site and to complete study procedures and questionnaires

  5. consent to participate in the study by signing the IRB/EC approved informed consent form

Exclusion Criteria:
  1. have any of the following conditions in the index joint:
  • Intra-articular corticosteroid therapy (or any other intra-articular therapy) in the study knee within 3 months of study enrollment

  • Significant varus or valgus deformities (>15º)

  • Incomplete or insufficient tissue surrounding the knee

  • Collateral ligament insufficiency

  • Inadequate bone stock to support the device (e.g., severe osteopenia/osteoporosis) or will require use of femoral and tibial stems

  • History of prior TKA

  1. have any of the following conditions in the contralateral joint:
  • a previous TKA as a revision for a failed total or unicondylar knee arthroplasty

  • a primary TKA or unicondylar knee arthroplasty that is not fully healed and well-functioning as determined by the Investigator

  1. have any of the following conditions of the hip:
  • a previous contralateral or ipsilateral revision hip arthroplasty

  • ipsilateral hip arthritis resulting in flexion contracture

  • previously received an ipsilateral or contralateral primary total hip arthroplasty or hip resurfacing arthroplasty that is not fully healed and well-functioning as determined by the Investigator

  1. have a diagnosis of an immunosuppressive disorder

  2. have an active infection, treated or untreated, systemic or at the site of the planned surgery

  3. have conditions that may interfere with the TKA survival or outcome, including but not limited to: Paget's disease, Charcot's disease, vascular insufficiency, muscular atrophy, uncontrolled diabetes, renal insufficiency or neuromuscular disease

  4. have a BMI > 40

  5. be facing current or impending incarceration

  6. have a known allergy to study device or one or more of its components

  7. be pregnant or have plans to become pregnant during the course of the study

  8. have, in the opinion of the Investigator, an emotional or neurological condition that would pre-empt their ability or willingness to participate in the study including mental illness, mental retardation, drug or alcohol abuse

  9. be enrolled in another drug, biologic, or device study within 30 days of screening

  10. be known to be at risk for lost to follow-up or failure to return for scheduled visits

  11. during the surgery, have a cruciate ligament tibial bone island that is secured with any fixative device (e.g. screw, plate, etc.).

Contacts and Locations

Locations

Site City State Country Postal Code
1 Loma Linda University Dept. of Orthopaedic Surgery Loma Linda California United States 92354
2 Holy Cross Orthopedic Institute Fort Lauderdale Florida United States 33334
3 Castle Orthopaedics & Sports Medicine, S.C. Aurora Illinois United States 60504
4 Midwest Orthopaedics at Rush Chicago Illinois United States 60612
5 Anne Arundel Medical Center Annapolis Maryland United States 21401
6 DeClaire LaMacchia Orthopaedic Institute Rochester Michigan United States 48307
7 Reno Orthopaedic Center Reno Nevada United States 89503
8 Mercer Bucks Orthopaedics Hamilton New Jersey United States 08691
9 NYU Hospital for Joint Diseases / NYU Langone Medical Center New York New York United States 10003
10 Hospital for Special Surgery New York New York United States 10021
11 Columbia University Center for Hip & Knee Replacement New York New York United States 10032
12 The Lindner Research Center at the Christ Hospital Cincinnati Ohio United States 45219
13 Oregon Health & Science University Portland Oregon United States 97239
14 Providence Regional Medical Center Everett Everett Washington United States 98201

Sponsors and Collaborators

  • Smith & Nephew, Inc.

Investigators

  • Study Chair: Stacy Leake-Gardner, Smith & Nephew, Inc.

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Smith & Nephew, Inc.
ClinicalTrials.gov Identifier:
NCT03136887
Other Study ID Numbers:
  • 16-4049-06
  • U1111-1191-7751
First Posted:
May 2, 2017
Last Update Posted:
Jan 18, 2020
Last Verified:
Jan 1, 2020
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
Yes
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jan 18, 2020